Teva Receives Approval For SYNRIBOTM

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S.Food and Drug Administration (FDA) approved SYNRIBO (omacetaxinemepesuccinate) for Injection to treat adult patients with chronic phase (CP)or accelerated phase (AP) chronic myeloid leukemia (CML) with resistanceand/or intolerance to two or more tyrosine kinase inhibitors (TKIs). Theindication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with SYNRIBO. Itwill be available for prescribing shortly.Previously, CP and AP CML patients who failed on two or more TKIs have hadlimited treatment options. “While the CML treatment landscape has seenadvancements with available TKI treatments, there are still cases wherepatients may not be able to continue using TKIs due to issues such asresistance, intolerance, suboptimal response, and disease progression,” saidJorge E. Cortes, M.D., deputy chair and professor of medicine in theDepartment of Leukemia at The University of Texas MD Anderson CancerCenter. “With SYNRIBO, physicians will now have access to another option,offering potential hope to patients who experience treatment failure.”